GNF2133

CAS No. 2561414-56-8

GNF2133( —— )

Catalog No. M28282 CAS No. 2561414-56-8

GNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 357 Get Quote
10MG 530 Get Quote
25MG 851 Get Quote
50MG 1152 Get Quote
100MG 1557 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    GNF2133
  • Note
    Research use only, not for human use.
  • Brief Description
    GNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes.
  • Description
    GNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes.(In Vitro):GNF2133 has an IC50 of >50 μM for GSK3β. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion.(In Vivo):In Diphtheria toxin A (RIP-DTA) mice, GNF2133 (3, 10, 30 mg/kg) significantly improves glucose disposal capacity and increased insulin secretion. In CD-1 mice, GNF2133 (30 mg/kg; p.o.) shows moderate plasma exposure and good oral absorption with oral bioavailability of 22.3%. In Wistar Han rat, GNF2133 (30 mg/kg; p.o.) increases in cell proliferation marker Ki67 and insulin and reduces cyclin D1 levels and overall cell density.
  • In Vitro
    ——
  • In Vivo
    GNF2133 (30 mg/kg; p.o.) shows good oral absorption with oral bioavailability of 22.3%.GNF2133 (30 mg/kg; p.o.; once a day for 5 days) shows the ability to proliferate β-cells in vivo.GNF2133 (3, 10, 30 mg/kg) significantly improves glucose disposal capacity and increased insulin secretion in RIP-DTA mice.Pharmacokinetic Parameters of GNF2133 in CD-1 mice.CD-1 mice; 30 mg/kg; p.o.. Animal Model:CD-1 mice Dosage:30 mg/kg Administration: P.o.Result:Showed good oral absorption and moderate plasma exposure with oral bioavailability of 22.3%.Animal Model:Wistar Han rat Dosage:30 mg/kg (0.5% methylcellulose + Tween-80)Administration:P.o.; once a day for 5 days Result:Increased cyclin D1 levels and overall cell density, and increased in cell proliferation marker Ki67 and insulin.Animal Model:Diphtheria toxin A (RIP-DTA) miceDosage:3, 10, 30 mg/kg (20 mg/kg doxycycline (Dox) for 5 days)Administration:P.o., once a day for 35 daysResult:Significantly improves glucose disposal capacity and increased insulin secretion.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    VEGFR|Tyrosine Kinases
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2561414-56-8
  • Formula Weight
    434.53
  • Molecular Formula
    C24H30N6O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 4 mg/mL (9.21 mM)
  • SMILES
    O=C(NC1=NC=CC(=C1)C2=CN(C=3C=NC=CC23)C4CCOCC4)N5CCN(CC)CC5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Yukitsuka Kudo, et al. Benzoxazole derivatives. US7910579B2
molnova catalog
related products
  • PS 48

    PS 48 has been shown to be a PKB Kinase (PDK1) activator (Kd: 10.3 μM). This compound selectively binds to the PIF-binding pocket of PKB Kinase (PDK1).

  • 1,2-Dimyristoyl-sn-g...

    1,2-dimyristoyl-sn-glycerol is able to increase AChE activity by 35-40% at concentrations of 25 micrograms/ml in the parasite S. mansoni..

  • rac-NBI-74330

    rac-NBI-74330 is an effective and selective CXCR3 antagonist.